890 related articles for article (PubMed ID: 16842246)
1. KIT immunohistochemistry and mutation status in gastrointestinal stromal tumours (GISTs) evaluated for treatment with imatinib.
Loughrey MB; Trivett M; Beshay V; Dobrovic A; Kovalenko S; Murray W; Lade S; Turner H; McArthur GA; Zalcberg J; Waring PM
Histopathology; 2006 Jul; 49(1):52-65. PubMed ID: 16842246
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of KIT-negative gastrointestinal stromal tumours and diagnostic utility of protein kinase C theta immunostaining.
Lee HE; Kim MA; Lee HS; Lee BL; Kim WH
J Clin Pathol; 2008 Jun; 61(6):722-9. PubMed ID: 18381383
[TBL] [Abstract][Full Text] [Related]
3. Analysis of mutation and expression of c-kit and PDGFR-alpha gene in gastrointestinal stromal tumor.
Zheng S; Chen LR; Wang HJ; Chen SZ
Hepatogastroenterology; 2007 Dec; 54(80):2285-90. PubMed ID: 18265649
[TBL] [Abstract][Full Text] [Related]
4. Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital.
Yeh CN; Chen TW; Lee HL; Liu YY; Chao TC; Hwang TL; Jan YY; Chen MF
Ann Surg Oncol; 2007 Mar; 14(3):1123-8. PubMed ID: 17195905
[TBL] [Abstract][Full Text] [Related]
5. [Activating mutations in receptor tyrosine kinases with relevance for treatment of gastrointestinal stromal tumors].
Wardelmann E; Merkelbach-Bruse S; Büttner R; Schildhaus HU
Verh Dtsch Ges Pathol; 2007; 91():165-8. PubMed ID: 18314611
[TBL] [Abstract][Full Text] [Related]
6. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.
Wardelmann E; Merkelbach-Bruse S; Pauls K; Thomas N; Schildhaus HU; Heinicke T; Speidel N; Pietsch T; Buettner R; Pink D; Reichardt P; Hohenberger P
Clin Cancer Res; 2006 Mar; 12(6):1743-9. PubMed ID: 16551858
[TBL] [Abstract][Full Text] [Related]
7. Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling.
Tarn C; Merkel E; Canutescu AA; Shen W; Skorobogatko Y; Heslin MJ; Eisenberg B; Birbe R; Patchefsky A; Dunbrack R; Arnoletti JP; von Mehren M; Godwin AK
Clin Cancer Res; 2005 May; 11(10):3668-77. PubMed ID: 15897563
[TBL] [Abstract][Full Text] [Related]
8. [Expression and gene mutation of phospho-platelet derived growth factor receptor alpha and C-kit in gastrointestinal and extra-gastrointestinal stromal tumors].
Tang M; Li DQ
Zhonghua Wei Chang Wai Ke Za Zhi; 2008 Jan; 11(1):80-3. PubMed ID: 18197502
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1.
Mussi C; Schildhaus HU; Gronchi A; Wardelmann E; Hohenberger P
Clin Cancer Res; 2008 Jul; 14(14):4550-5. PubMed ID: 18628470
[TBL] [Abstract][Full Text] [Related]
10. An immunohistochemical and molecular study of gastrointestinal stromal tumours.
Teong YT; Teo ST; Tan LP; Wu BQ; Peh SC
Med J Malaysia; 2006 Dec; 61(5):526-33. PubMed ID: 17623951
[TBL] [Abstract][Full Text] [Related]
11. Platelet-derived growth factor receptor family mutations in gastrointestinal stromal tumours.
Sihto H; Franssila K; Tanner M; Vasama-Nolvi C; Sarlomo-Rikala M; Nupponen NN; Joensuu H; Isola J
Scand J Gastroenterol; 2006 Jul; 41(7):805-11. PubMed ID: 16785193
[TBL] [Abstract][Full Text] [Related]
12. Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: a potential diagnostic pitfall.
Pauwels P; Debiec-Rychter M; Stul M; De Wever I; Van Oosterom AT; Sciot R
Histopathology; 2005 Jul; 47(1):41-7. PubMed ID: 15982322
[TBL] [Abstract][Full Text] [Related]
13. KIT and PDGFRalpha mutational analyses of mixed cell-type gastrointestinal stromal tumours.
Wong NA; Mangwana S
Histopathology; 2007 Dec; 51(6):758-62. PubMed ID: 18042065
[TBL] [Abstract][Full Text] [Related]
14. Pathology of gastrointestinal stromal tumors.
Hirota S; Isozaki K
Pathol Int; 2006 Jan; 56(1):1-9. PubMed ID: 16398673
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.
Lasota J; Miettinen M
Histopathology; 2008 Sep; 53(3):245-66. PubMed ID: 18312355
[TBL] [Abstract][Full Text] [Related]
16. A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.
Ryu MH; Kang WK; Bang YJ; Lee KH; Shin DB; Ryoo BY; Roh JK; Kang JH; Lee H; Kim TW; Chang HM; Park JO; Park YS; Kim TY; Kim MK; Lee WK; Kang HJ; Kang YK
Oncology; 2009; 76(5):326-32. PubMed ID: 19307738
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes.
Liegl B; Hornick JL; Corless CL; Fletcher CD
Am J Surg Pathol; 2009 Mar; 33(3):437-46. PubMed ID: 19011564
[TBL] [Abstract][Full Text] [Related]
18. c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors.
Miselli FC; Casieri P; Negri T; Orsenigo M; Lagonigro MS; Gronchi A; Fiore M; Casali PG; Bertulli R; Carbone A; Pierotti MA; Tamborini E; Pilotti S
Clin Cancer Res; 2007 Apr; 13(8):2369-77. PubMed ID: 17438095
[TBL] [Abstract][Full Text] [Related]
19. Genetic and pathologic characteristics of gastrointestinal stromal tumors in extragastric lesions.
Cho S; Kitadai Y; Yoshida S; Tanaka S; Yoshihara M; Yoshida K; Chayama K
Int J Mol Med; 2006 Dec; 18(6):1067-71. PubMed ID: 17089009
[TBL] [Abstract][Full Text] [Related]
20. PDGFRalpha- and c-kit-mutated gastrointestinal stromal tumours (GISTs) are characterized by distinctive histological and immunohistochemical features.
Pauls K; Merkelbach-Bruse S; Thal D; Büttner R; Wardelmann E
Histopathology; 2005 Feb; 46(2):166-75. PubMed ID: 15693889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
